about
Caplan's syndrome13 Caplan's syndromeMusculoskeletal problems of performing artists.Role of physical therapy in the management of common low back pain.Evaluation of patients with CNS involvement in SLE.Seronegative arthritis and the bowel.Tropical rheumatology. Immunological aspects.Immunopathogenesis of SLE.Maternal autoantibodies and pregnancy--II: The neonatal lupus syndrome.Dysbaric disorders: aseptic bone necrosis in tunnel workers and divers.What are the mechanisms of regional musculoskeletal pain?Shoulder disorders: a state-of-the-art reviewDrug-induced gout.Psoriatic arthritis. Genetics and HLA antigens.Sex hormones and the immune system--Part 1. Human data.Sex hormones and the immune system--Part 2. Animal data.Cytokine abnormalities in inflammatory arthritis.The role of cytokines and their inhibitors in arthritis.The search for laboratory measures of outcome in rheumatoid arthritis.Acute phase reactants in predicting disease outcome.The role of heat shock protein in the persistence of arthritis.Biopsychosocial analysis of low back pain.Epidemiology of low back pain.Back pain in children and teenagers.Can low back pain disability be prevented?Medical approach to low back pain.Psychosocial issues in the prevention of chronic low back pain--a literature review.Back schools in prevention of chronicity.Prevention of low back pain: basic ergonomics in the workplace and the clinic.Management of early inflammatory arthritis. The long-term outcome and justification for early treatment.Objectives and outcome of running an early inflammatory arthritis clinic.Reactive arthritis: the role of bacterial antigens in inflammatory arthritis.The HLA class II component of susceptibility to rheumatoid arthritis.Management of early inflammatory arthritis. Genetic factors predicting persistent disease: the role of defective enzyme systems.Markers of bone and collagen breakdown in early inflammatory arthritis.Bone densitometry measurements in early inflammatory disease.Management of early inflammatory arthritis. Intervention with immunomodulatory agents: monoclonal antibody therapy.Management of early inflammatory arthritis. Intervention with immunomodulatory agents: T cell vaccination.Management of early inflammatory arthritis. Intervention with immunomodulatory agents: new pharmacological developments.The course of rheumatoid arthritis.
P1433
Q28270320-27F46A89-B10B-4873-A821-D3D8A82527BDQ29037602-14E4F672-0CC5-400B-912C-F045FC83CEE6Q30421026-7E549B87-B25D-46CE-AF45-2920D53810E0Q31042481-DF7F7075-15D1-4AAA-9CB9-A118149786A5Q31933342-7C12EED0-C3EF-4182-B217-6A3DE8096020Q33362182-0C6DFF50-CC9B-4305-8912-6BF51E17D96BQ33366947-9BCD718F-BD83-44EF-B148-4B72D18FB450Q33368979-1EEF910B-249D-42A8-B398-3A93C424200DQ33402503-E0900CEE-9F1D-4652-9F2A-49192FE78A19Q33466641-79A4DBE2-1D75-47D9-9C9A-DF4E193EFAF2Q33710116-5826CA33-6AFF-4CE0-9DD9-BAF01C4356E5Q33710122-A0778A0E-8E63-4D2B-AA8F-B39FFA5CE32EQ34130901-87F918D9-109C-46B0-A6AC-4786C7DCD83BQ34333119-8BC6FD4F-A0F7-48B3-9CD7-364191F0B4D6Q34349251-094F6139-F29A-4D59-A47E-F58F15FD4297Q34349269-EFB9D8CF-0401-48E4-BBAD-CA17BAC08EA2Q35233161-870F6D39-C69D-473C-B0AF-C03AA67DD049Q35233166-859DF663-332E-4712-9F20-6DB655D32533Q35314485-100E85D6-5EC9-45A6-B87F-0A233520F8F2Q35336573-F4D315D2-ACD6-45A7-813F-36CC7A8DC665Q35351365-9C60FAB0-8877-44D4-A114-F202DB5CFA5BQ35653834-92A222F5-0244-4A32-BC1A-3180C99B4DD2Q35653841-5FACDBE2-5DB1-459F-ACE5-3BD5B84DB677Q35653847-E92E05DB-1706-45D3-9C1D-C7B5720A53F1Q35653854-66966030-9C47-49FC-B609-463667CCB843Q35653859-E27DD6D2-35E7-44DC-8F27-F7E691C9C2AEQ35653865-274376DC-10D1-4785-B388-DD5669C6014CQ35653869-A84B1CCC-E63E-4C6F-853C-331901B7DB48Q35653874-2702CD71-A053-453F-91C7-9E9B48004E87Q35838697-E9B9B493-CCC5-492D-8200-893FEEB163B1Q35838702-525580E4-AF7D-4A45-98E9-5D9ECF293BFFQ35838706-09B0AC4A-B061-4335-BA36-80B3FFC327A1Q35838720-0D35FAE1-9DDE-4280-BC2F-6FA72155194AQ35838724-C2AA187F-4BAF-41B7-95D2-4490BC1C3154Q35838740-DBA07730-4288-407B-81C0-B0B70CA1766EQ35838748-CB88DA17-9B34-49DA-8402-BC1943991987Q35838765-96C16BA4-5F53-49A0-BB15-2EDB30863B2FQ35838783-836827B7-AC2C-4C09-A638-A02850AC0D19Q35838787-D489490E-F76E-4DA4-BFB2-372E7932E219Q35998689-60D1B897-28B9-4DE0-A93C-72B5301924E2
P1433
description
czasopismo naukowe
@pl
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
Bailliere's clinical rheumatology
@ast
Bailliere's clinical rheumatology
@en
Bailliere's clinical rheumatology
@es
Bailliere's clinical rheumatology
@it
Bailliere's clinical rheumatology
@nl
type
label
Bailliere's clinical rheumatology
@ast
Bailliere's clinical rheumatology
@en
Bailliere's clinical rheumatology
@es
Bailliere's clinical rheumatology
@it
Bailliere's clinical rheumatology
@nl
altLabel
Baillieres Clin Rheumatol
@en
prefLabel
Bailliere's clinical rheumatology
@ast
Bailliere's clinical rheumatology
@en
Bailliere's clinical rheumatology
@es
Bailliere's clinical rheumatology
@it
Bailliere's clinical rheumatology
@nl
P3181
P1055
P1156
P1476
Bailliere's clinical rheumatology
@en